US FDA approves ciltacabtagene autoleucel (CARVYKTI) for relapsed or refractory myeloma

Access, MyelomaLeave a comment

The US Food and Drug Administration (FDA) has approved the CAR-T treatment ciltacabtagene autoleucel (also known as cilta-cel and marketed as Carvykti). Manufactured by Janssen, it is specifically approved for the treatment of patients with relapsed or refractory myeloma after four or more prior lines of therapy, including a proteasome inhibitor (like bortezomib), an immunomodulatory agent (like lenalidomide), and an anti-CD38 monoclonal antibody (like daratumumab or isatuximab). You can find the full Janssen press release…

A note from MPE on the situation in Ukraine

MPELeave a comment

Given the recent events on the world stage, we felt it was necessary to highlight our concern at the developing situation in Ukraine and to reiterate our support to patients, carers and our fellow patient advocacy groups within the country and in surrounding countries. Myeloma Patients Europe is a collaborative association of patient groups striving for better treatments and care for myeloma and AL amyloidosis patients in Europe. We strongly believe that all patients should have access to the best…

Access to generic lenalidomide (e.g. Revlimid) in Europe

Access, MyelomaLeave a comment

Sandoz, a manufacturer of generic medicines, announced the launch of generic lenalidomide in 19 European countries. You can see the full press statement here.    Alternatively known under the branded name “Revlimid”, lenalidomide is a drug licensed and commonly used in the treatment of myeloma – in newly diagnosed, maintenance and relapsed settings.   Lenalidomide was first approved by the European Medicines Agency (EMA) in 2008 and has been solely marketed in Europe by Celgene…

Myeloma Patients Europe appoints Interim CEO

MPELeave a comment

Myeloma Patients Europe (MPE) is pleased to share that Hans Scheurer, President of MPE, will be acting as Interim Chief Executive Officer (CEO) until a permanent CEO is appointed in the coming months.   This follows last year’s news that the founding CEO of MPE, Ananda Plate, has stood down from the role after ten very successful years.   Hans will be supported in his role as Interim CEO by a formal management committee, who…

MPE launches survey on myeloma and AL amyloidosis diagnosis

AL amyloidosis, MPE, Myeloma, Patient evidenceLeave a comment

As part of MPE’s Year of Action, we are excited to announce the launch of the survey on myeloma and AL amyloidosis diagnosis. At MPE, we know that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare. The survey seeks to understand the perspectives of myeloma and AL amyloidosis patients, as well as haematologists, on the diagnosis challenges. The survey will take approximately 5 minutes to complete and is…

MPE Publishes 2021: Year in Review

MPELeave a comment

Today Myeloma Patients Europe (MPE) published our 2021: Year in Review, a snapshot of the major accomplishments from the past year.   In 2021, MPE launched two projects that will provide distinct and indispensable resources for the patient community: the launch of the redesigned Myeloma Access Atlas, helping the patient community to advocate more effectively for equal access to medicines, and the development of the European Myeloma Clinical Trial Navigator, which will significantly improve patients’…